|
WO2020060983A2
|
|
Orally active melanocortin receptor-4 compounds
|
|
CN112188888A
|
|
Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
|
|
WO2016168388A2
|
|
Therapies for obesity, diabetes and related indications
|
|
WO2015175502A2
|
|
Replacement therapy for natriuretic peptide deficiencies
|
|
CN104755094A
|
|
Uses of Bremelanotide in therapy for female sexual dysfunction
|
|
AU2011242696A1
|
|
Uses of natriuretic peptide constructs
|
|
CN102725305A
|
|
Melanocortin-1 receptor-specific cyclic peptides
|
|
EP2504351A1
|
|
Melanocortin-1 receptor-specific linear peptides
|
|
EP2440572A2
|
|
Lactam-bridged melanocortin receptor-specific peptides
|
|
AU2010259008A1
|
|
Melanocortin receptor-specific peptides
|
|
WO2010065800A1
|
|
Hydrazine substituted piperidine melanocortin receptor-specific compounds
|
|
WO2010065801A1
|
|
Amine substituted piperazine melanocortin receptor-specific compounds
|
|
WO2010037081A1
|
|
Melanocortin receptor-specific spiro-piperidine compounds
|
|
US2009305960A1
|
|
Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
|
|
CN102131514A
|
|
Melanocortin receptor-specific peptides for treatment of sexual dysfunction
|
|
WO2009120656A1
|
|
Pharmaceutical for ocular indications
|
|
ZA200809191B
|
|
Cyclic natriuretic peptide constructs
|
|
US2009076029A1
|
|
Compounds and Methods for Treating Obesity
|
|
WO2009144433A1
|
|
Methods for selection of melanocortin 4 receptor-specific agents for treatment of obesity
|
|
WO2009144432A1
|
|
Mc4-r agonists for the treatment of obesity
|
